Loading
A phase 1/2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by BioInvent International AB, active and no longer recruiting.
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06205706 by BioInvent International AB, with 35 participants enrolled, started 2023-12-04 and due to reach its primary completion in 2027-07-14. Interventions recorded: BI-1910, Pembrolizumab. Conditions listed: Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Shares BioInvent International, Pembrolizumab, Immune checkpoint inhibitors.
Shares BioInvent International, Pembrolizumab, Immune checkpoint inhibitors.